Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by Greenviolinoon Dec 16, 2019 2:44pm
310 Views
Post# 30460305

Don’t give up on Trog and Egrifta sales

Don’t give up on Trog and Egrifta sales

In my opinion, there is too much expectation put on the NASH project. I do not believe NASH will double or triple the price of the stock given the competition in that field of research at this time. Yes the stock will react to a Phase III announcement, but management will need to indicate the potential sales just like it did with Trogarzo at the time. The anticipated market size and sales for Trogarzo are what really fueled the stock price.
Now even with slower Trogarzo sales, we own a company that generates around $80 million - and perhaps closer to $100 million in a year in sales. Don't you think the company owes shareholders a business plan to make a profit on those sales? When you sell a product and you don't make any money on it, either your price is too low or your costs are too high. I would challenge TH management on this issue, ie make a profit out of the sales generated. Convince the market that they are efficient operators and are following a clear plan, as well as showing vision for the future.
Show us a plan that will generate EPS of 0.10, 0.15, 0.25. Gaining confidence will bring investors, not wishful thinking.

 

Bullboard Posts